Did Supernus Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SUPN
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
3 Small-Cap Stocks Skating on Thin Ice
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street ...
Levi & Korsinsky Announces an Investigation on Behalf of Supernus Pharmaceuticals, Inc. (SUPN) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / March 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
Hosted on MSN16d
Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results , with sales up 6% year on ...
Hosted on MSN17d
What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know. Supernus Pharmaceuticals beat ...
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday. Separately, Cantor ...
Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts
We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are ...
Yahoo Finance9d
Supernus to Participate in Two Upcoming Investor Conferences
Supernus Pharmaceuticals, Inc. ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and ...
Benzinga.com22d
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus' SPN-820 failed to show significant improvement in depression severity in its Phase 2b study, with no difference from placebo. The safety profile of SPN-820 remained consistent with ...
Reuters23d
Supernus' depression treatment fails mid-stage trial, shares plunge
Feb 18 (Reuters) - Supernus Pharmaceuticals (SUPN.O), opens new tab said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its ...
Investing2d
Supernus at Barclays Conference: Strategic Growth and Innovation
On Tuesday, 11 March 2025, Supernus Pharmaceuticals (NASDAQ: SUPN) presented at the Barclays 27th Annual Global Healthcare Conference, outlining its strategic direction and financial performance.
Investing2d
Supernus at Barclays Conference: Strategic Growth and Innovation
On Tuesday, 11 March 2025, Supernus Pharmaceuticals (NASDAQ: SUPN) presented at the Barclays 27th Annual Global Healthcare Conference, outlining its strategic direction and financial performance. The ...